MediWound Completes Recruitment of Commercial Management Team in Europe
GlobeNewswire - Mon May 12, 7:01AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces completion of recruitment of its commercial management team in Europe and its intention to promote and appoint three executive officers in support of planned commercial European launch and international expansion of its lead product, NexoBrid, as well as its research and development efforts.
MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica
GlobeNewswire - Thu May 08, 6:08AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signing of an agreement granting Genfa Medica, S.A. exclusive rights to market and distribute NexoBridin Russia for the treatment of severe burns. Approximately 35,000 patients with severe burns are hospitalized every year in Russia at approximately 80 burn centers.
MediWound Announces Extraordinary General Meeting of Shareholders
GlobeNewswire - Mon May 05, 3:41PM CDT
MediWound Ltd. (Nasdaq:MDWD) (the "Company"
MediWound Reports First Quarter 2014 Financial Results
GlobeNewswire - Fri May 02, 5:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports today its financial results for the three months ended March 31, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 23, 12:37PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why MediWound (MDWD) Stock Is Up Today
at The Street - Wed Apr 16, 11:07AM CDT
Coverage was initiated on MediWound (MDWD) with an 'outperform' rating by Oppenheimer
MediWound Announces Closing of Initial Public Offering
GlobeNewswire - Tue Mar 25, 11:20AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, today announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of $14.00 per share. All of the shares of common stock in the offering were offered by MediWound and include 750,000 shares issued pursuant to the full exercise of the underwriters' 30-day option to purchase up to 750,000 additional shares at the initial public offering price.
3 IPOs launched, more on Fri.
at Investor's Business Daily - Thu Mar 20, 5:47PM CDT
Shares of Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for kidney disease, priced at 17 and opened at 22.90. Shares ended the day at 26.69. Q2 Holdings (QTWO), which provides online banking services, priced at 13 and...
IPO Sizzle Continues With A10 Networks Set For Friday
at Investor's Business Daily - Thu Mar 20, 1:03PM CDT
Three IPOs launched Thursday, continuing a hot streak that will carry into Friday when A10 Networks (ATEN) is set to debut. A top performer Thursday was Akebia Therapeutics (AKBA), a biopharmaceutical company focused on therapies for patients with...
Akebia and MediWound rise as health IPOs continue
AP - Thu Mar 20, 11:11AM CDT
NEW YORK (AP) — Drug developer Akebia Therapeutics and burn treatment maker MediWound both went public Thursday as the tide of health care IPOs continued to rise.
MediWound Prices Initial Public Offering
GlobeNewswire - Thu Mar 20, 6:00AM CDT
MediWound Ltd., a fully-integrated, biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announced today the pricing of its initial public offering of 5,000,000 ordinary shares at a price to the public of $14.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on March 20, 2014 under the symbol "MDWD." MediWound has granted the underwriters a 30-day option to purchase up to 750,000 additional shares at the initial public offering price.
Paylocity IPO Pops, Maintaining New-Issue Enthusiasm
at Investor's Business Daily - Wed Mar 19, 11:12AM CDT
The Paylocity Holding (PCTY) IPO jumped Wednesday, setting the stage for nine more IPOs this week, as new issues remain hot. Paylocity priced at 17 on Tuesday evening, above its expected range, and opened at 31 on the Nasdaq Wednesday morning. In...